More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

The USP, a standard-setting organization, has stated that that it will not develop a new monograph for a biologic unless there is stakeholder consensus supporting its creation, including support from the FDA. In making that decision, the USP...

How did the pharmaceutical industry perform in 2017, and what is the outlook for 2018 and beyond? Key for the industry is the performance of the US market, the largest national market in the global pharmaceutical industry, but what other factors...

An effective supply strategy is crucial for pharmaceutical companies, so what are the challenges that companies face? Managing risk, addressing shifts in product mix, and increasingly complex supply chains are some of the challenges. The DCAT Week...

Biopharmaceutical companies invest approximately $75 billion annually in R&D in the US, more than any other industry in the US. There are more than 7,000 drugs in development, with more than three-quarters defined as first-in-class, meaning...

A recent study by PwC examines the thinking and strategic direction of CEOs and how their views compare with the perceptions and expectations of investment professionals. So what did the study show? Investment professionals and CEOs both think...